MacroGenics Inc. (MGNX) is expected to grow earnings and revenues in the years ahead

MacroGenics Inc. [MGNX] stock prices are up down -4.75% to $3.01 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The MGNX shares have lost -14.97% over the last week, with a monthly amount drifted -20.79%, and not seem to be holding up well over a long-time horizon.

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.

Sponsored

From an analyst’s perspective:

MacroGenics Inc. [NASDAQ: MGNX] stock has seen the most recent analyst activity on July 18, 2022, when SMBC Nikko downgraded its rating to a Neutral but kept the price target unchanged to $5 for it. Previously, BMO Capital Markets downgraded its rating to Market Perform on July 11, 2022, and dropped its price target to $4. On May 04, 2022, downgrade downgraded it’s rating to Neutral. Citigroup upgraded its rating to a Buy and decreased its price target to $21 on February 28, 2022. BMO Capital Markets initiated its recommendation with a Outperform and recommended $31 as its price target on February 11, 2022. SMBC Nikko started tracking with a Outperform rating for this stock on February 04, 2022, and assigned it a price target of $40.

The stock price of MacroGenics Inc. [MGNX] has been fluctuating between $2.13 and $22.68 over the past year. Currently, Wall Street analysts expect the stock to reach $10.72 within the next 12 months. MacroGenics Inc. [NASDAQ: MGNX] shares were valued at $3.01 at the most recent close of the market. An investor can expect a potential return of 256.15% based on the average price forecast.

Analyzing the MGNX fundamentals

The most recent quarter, MacroGenics Inc. [NASDAQ:MGNX] reported sales of 26.01 billion, representing a drop of -15.60%. Gross Margin for this corporation currently stands at +82.04% with Operating Margin at -261.85%, Pretax Margin comes in at -260.97%, and Net Margin reading is -260.97%.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.95 points at the first support level, and at 2.88 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.10, and for the 2nd resistance point, it is at 3.18.

MacroGenics Inc. [MGNX] reported earnings per share of -$1.08 for its fiscal quarter that ended on 3/30/2022. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.86/share, meaning a difference of $-0.22 and a surprise factor of -25.60%. By comparison, the stated earnings for the previous quarter ended on 12/30/2021 were -$0.95 per share as compared to estimates of -$0.81 per share, a difference of $-0.14 representing a surprise of -17.30%.

Ratios To Look Out For

It’s worth pointing out that MacroGenics Inc. [NASDAQ:MGNX]’s Current Ratio is 3.30. On the other hand, the Quick Ratio is 3.69, and the Cash Ratio is 3.27. Considering the valuation of this stock, the price to sales ratio is 12.42, the price to book ratio is 4.11.

Transactions by insiders

The next item on our agenda is insider trading, which has seen 0 insider purchases totaling 0 shares and 0 insider sales totaling 0 shares over the past 3 months. Recent insider trading involved Karrels James, SVP, CFO and Secretary, that happened on Jun 15 when 40000.0 shares were purchased. 10% Owner, BIOTECH TARGET N V completed a deal on Nov 19 to buy 0.2 million shares. Meanwhile, 10% Owner BIOTECH TARGET N V bought 100000.0 shares on Sep 29.